Andere Sprachen Insulet Corporation

Aktien

A0MQX8

US45784P1012

PODD

Medizinische Versorgung

Realtime-Estimate Cboe BZX Andere Börsenplätze 19:11:06 11.06.2026			% 5 Tage	Veränd. 1. Jan.
148,36 ^USD	-1,56 %		+1,10 %	-47,93 %

09.06.	INSULET CORPORATION : Raymond James behält die Bewertung Kaufen bei	ZM
06.06.	Insulet Corporation präsentiert neue Daten zu Omnipod 6 und vollautomatisierten Closed-Loop-Systemen zur Insulinabgabe	CI

Andere Sprachen

08:09	Divided Federal Circuit Panel Nixes $452 Million Trade Secret Judgment As Time-Barred
06.06.	Insulet Corporation Reveals New Data Supporting Omnipod 6 And Fully Closed-Loop Automated Insulin Delivery Systems
06.06.	Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care
05.06.	Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions
04.06.	Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions
03.06.	Insulet Insider Bought Shares Worth $497,490, According to a Recent SEC Filing
03.06.	Insulet Rolls Out Omnipod 5 With Enhanced Algorithm, Abbott Libre 3 Plus Compatibility
03.06.	Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott’s FreeStyle Libre 3 Plus Sensor
03.06.	Insulet Corporation Announces U.S. Rollout of Enhanced Omnipod 5 Algorithm and Expands Compatibility with Abbott?S Freestyle Libre 3 Plus Sensor
28.05.	US appeals court overturns Insulet's $59 million (not $452 mln) insulin-pump trade secret verdict against rival Eoflow
28.05.	US court overturns Insulet's $59 million insulin-pump trade secret verdict against EOFlow
28.05.	US appeals court overturns Insulet's $452 mln insulin-pump trade secret verdict against rival EOFlow
27.05.	Insulet to Participate in William Blair 46th Annual Growth Stock Conference
27.05.	Insulet Device Correction Seen as Setback, Long-Term Targets Intact, RBC Says
26.05.	Insulet initiates voluntary medical device correction for certain Omnipod® pods in the U.S. and affected international markets
26.05.	Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® Pods in the U.S. and Affected International Markets
26.05.	Insulet Initiates Voluntary Medical Device Correction For Certain Omnipod Pods In The U.S. And Affected International Markets
19.05.	The DTSA Turns Ten: What A Decade Of Litigation Tells Us
06.05.	Tranche Update on Insulet Corporation's Equity Buyback Plan announced on May 8, 2025.
06.05.	Insulet Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026
06.05.	Insulet Q1 Adjusted Net Income, Revenue Increase; Lifts 2026 Omnipod Revenue Growth Guidance
06.05.	Earnings Flash (PODD) Insulet Posts Q1 Revenue $761.7M, vs. FactSet Est of $729.9M
06.05.	Earnings Flash (PODD) Insulet Posts Q1 Adjusted EPS $1.42, vs. FactSet Est of $1.20
06.05.	Insulet lifts annual revenue forecast after quarterly beat on strong insulin pump demand
06.05.	Earnings Flash (PODD) Insulet Corporation Posts Q1 Adjusted EPS $1.42 per Share, vs. FactSet Est of $1.20